As per DelveInsight, the global Immunomodulators market is estimated to grow at a CAGR of 5.19% during the forecast period from 2023 to 2028. The rising incidence of numerous chronic diseases like asthma, allergy disorders, cancer, multiple sclerosis, and others around the world is primarily driving up demand for immunomodulators. The development of immunotherapeutic drugs for the treatment of multiple types of sclerosis, such as ponesimod, ozanimod, and laquinimod, as well as improvements in drug delivery technologies, rising use of an early immunomodulator therapy for the treatment of Crohn’s disease, the existence of significant unmet clinical needs regarding the treatment of immune disorders, such as rheumatoid arthritis, and an increase in drug launches and approvals, are also immensely contributing to the Global Immunomodulators Devices Market growth. Some of the major Immunomodulators Devices companies in the market include Pfizer Inc., Petrovax, Acrotech Biopharma, Inc., Astellas Pharma Inc., Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Biocon, Bristol-Myers Squibb Company, Teva Pharmaceuticals, Zydus Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Johnson & Johnson Services, Inc., and others.
DelveInsight’s “Immunomodulator Devices Market Insight, Competitive Landscape, and Market Forecast 2028” research report provides the current and forecasted Immunomodulator Devices market size, share, and trends analysis for the next five years. Moreover, it highlights the ongoing innovations in the segment, major market drivers & barriers, key competitors, and emerging devices in the domain.
Immunomodulators Devices Market: Overview
Immunomodulators modulate the immune system to help your body respond to a disease or illness. Immunomodulators are agents that can enable the body to fight cancer, infection, or other disorders by stimulating or suppressing the immune system. Immunomodulators are extensively used to treat multiple myeloma. Immunomodulators included adjuvants, cytokines, thymic products, hormones, glucocorticoids, host defense peptides, microbial products, probiotics, synthetic chemical compounds, toll-like receptors, nutrients, vitamins, minerals, herbs, panchgavya elements, polysaccharides, helminths, vaccines, and others.
To provide a better understanding of the market dynamics, DelveInsight’s “Immunomodulators Devices Market” report provides an in-depth assessment of the market by type (immunosuppressants and immunostimulants) and by indication (cancer, respiratory, HIV, and others). The immunosuppressants category is anticipated to amass a sizable revenue share in the drug type section of the immunomodulators market in the upcoming years. This can be attributed to the benefits and uses related to the segment. Further, the increasing product launches, approvals, and other strategic activities in the immunosuppressant drugs domain will also drive the market of the segment.
Immunomodulators Devices Market Analysis
The rising prevalence of chronic diseases worldwide is one of the key factors expected to drive the immunomodulators’ product demand and market growth. As per the estimate, the worldwide burden of cancer is predicted to increase to 27.5 million new cases and 16.3 million cancer deaths by 2040.
Because risk factors including smoking, poor food, physical inactivity, and fewer pregnancies are becoming more prevalent in economically developing nations, the burden will likely grow in the future. A class of medications known as immunomodulators focuses mostly on the pathways used to treat multiple myeloma and a few other malignancies. They can affect the immune system directly by reducing the levels of some proteins and increasing the levels of others. Therefore, the demand for immunomodulators will rise in the coming years as cancer incidence rises.
The future burden will probably be even larger due to the increasing prevalence of factors that increase risk, such as smoking, unhealthy diet, physical inactivity, and fewer childbirths, in economically transitioning countries. Immunomodulators are a group of drugs that mainly target the pathways that treat multiple myeloma and a few other cancers. They have many ways to work, including working on the immune system directly by turning down some proteins and turning up others. Thus, the increasing incidence of cancer will increase the demand for immunomodulators in the upcoming years. Patients with relapsing forms of multiple sclerosis (MS) should be treated with immunomodulators or receptor modulators. They aid in reducing the frequency of clinical exacerbations and slowing the progression of physical impairment. Therefore, the market’s demand for immunomodulators will rise as MS’s prevalence rises. Overall, the existing high unmet clinical needs concerning the treatment of immunological illnesses and their decreased risk of side effects when compared to other available medications are anticipated to drive the Immunomodulators Devices market growth in the upcoming years.
However, side effects related to drugs, stringent regulatory framework, and others may restrict the immunomodulators market growth.
Interested to know more about the ongoing developments in the market? Visit to get an in-depth insight @ Immunomodulators Devices Types and Emerging Products
Immunomodulators Devices – Global Market Assessment and Forecast
In terms of geographical market occupancy, North America is anticipated to hold the highest market share for immunomodulators in the upcoming years. The North America Immunomodulators market is anticipated to grow due to factors including the rise in the aging population susceptible to autoimmune disorders, a rising population base suffering from chronic diseases like asthma, allergic conditions, cancer, multiple sclerosis, and others, as well as the presence of key players in the region. Moreover, a high disposable income, an advanced healthcare system, and the regulatory approval of new pharmaceuticals are also anticipated to contribute to the Immunomodulators Devices market growth in the upcoming years. Strategic activities such as product launches and approvals, mergers, acquisitions, partnerships, and others also help in boosting the market.
Interested in knowing how the Immunomodulators Devices market will grow by 2028? Click to get a snapshot @ Immunomodulators Devices Market Trends and Developments
Immunomodulators Devices Market – Key Developments and Breakthroughs
Over the years, the Immunomodulators Devices market has evolved significantly, owing to the active participation of global MedTech companies and technological advancements in the domain. Similarly, several clinical, commercial, and regulatory developments have also been registered in the domain.
Some of the major advancements in the Immunomodulators Devices market in recent years include –
- In April 2023, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted ADvantage Therapeutics’ immunotherapy AD04 an Innovation Passport for the treatment of Alzheimer’s disease. The designation, under the regulator’s Innovative Licensing and Access Pathway (ILAP), will fast-track a potential route to market for AD04 by providing collaborative opportunities with UK institutes like the National Institute for Health and Care Excellence (Nice).
- In November 2022, Provention Bio, Inc., received Biologics License Application (BLA) approval from FDA for TZIELD (teplizumab-mzwv), an anti-CD3-directed antibody, for intravenous use, as the first and only immunomodulatory treatment to delay the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older with stage 2 T1D.
- In March 2022, Themis Medicare Ltd., announced the approval of its antiviral drug VIRALEX® by the Drug Controller General of India (DCGI). VIRALEX® is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body’s defense response to viral infections.
- In October 2019, Pandion Therapeutics, Inc., and Astellas Pharma Inc., signed a license and collaboration agreement directed toward the research, development, and commercialization of locally acting immunomodulators for autoimmune diseases of the pancreas.
Learn more about major clinical and commercial development in the Immunomodulators Devices Market @ Immunomodulators Devices Market – Clinical and Commercial Development Activities
Key Companies in the Immunomodulators Devices Market
Globally, some of the leading Immunomodulators Devices companies actively working in the market include Pfizer Inc., Petrovax, Acrotech Biopharma, Inc., Astellas Pharma Inc., Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Biocon, Bristol-Myers Squibb Company, Teva Pharmaceuticals, Zydus Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Johnson & Johnson Services, Inc., and others. Owing to the rising demand and favorable growth opportunities for revenue generation, several new players are anticipated to enter the market, thereby leading to high competitiveness in the domain.
Learn how new players’ entries will transform the Immunomodulators Devices market dynamics in the coming years @ Immunomodulators Devices Competitive Landscape
Scope of the Immunomodulators Devices Market Report:
- Study Period – 2020-2028
- Geography Covered – North America, Europe, Asia-Pacific, and Rest of the World
- Immunomodulators Devices Market Assessment –
-
- By Type – Immunosuppressants And Immunostimulants
- Indication – Cancer, Respiratory, HIV, And Others
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s Views
Table of Content
| 1 | Report Introduction |
| 2 | Executive Summary |
| 3 | Regulatory and Patent Analysis in the Immunomodulators Devices Market |
| 4 | Immunomodulators Devices Market Key Factors Analysis |
| 5 | Immunomodulators Devices Porter’s Five Forces Analysis |
| 6 | COVID-19 Impact Analysis on the Immunomodulators Devices Market |
| 7 | Immunomodulators Devices Market Layout |
| 8 | Immunomodulators Devices Companies Share Analysis – Top 3–5 Companies |
| 9 | Immunomodulators Devices Companies and Major Product Profiles |
| 10 | Project Approach |
| 11 | KOL Views on Immunomodulators Devices Market |
| 12 | DelveInsight Capabilities |
| 13 | Disclaimer |
| 14 | About DelveInsight |
Reach out to us to get a more detailed overview of the market @ Immunomodulators Devices Market Insights and Competitive Landscape
Other Trending Healthcare Reports by DelveInsight:
Image Guided Surgery Devices Market | Alopecia Market | Chronic Myelogenous Leukemia Market | Neuroblastoma Market | Alzheimer Disease Market | Osteoarthritis Market | Apheresis Market | Scleroderma Market | Hyperhidrosis Market | Opioid Induced Constipation Market | Cervical Intraepithelial Neoplasia Market | Automated External Defibrillators Market | Choroidal Neovascularization Market | Familial Primary Pulmonary Hypertension Market | Meningioma Market | Progressive Multifocal Leukoencephalopathy Market
Leverage the potential of consulting services to overcome the competition in the highly evolving and dynamic healthcare market with Healthcare Regulatory Analysis and Merger and Acquisitions in Healthcare Industry
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
Manager (Marketing & Branding)
info@delveinsight.com
+1(919)321-6187.